Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node–positive and high-risk lymph node–negative breast cancer (E5103). J Clin Oncol 2018; 36: 2621-2629.

Published: 22nd March 2019

Authors: Miller KD, O’Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA et al.

Conclusion

Some 4994 women were randomly allocated to one of three groups. Incorporation of bevacizumab did not improve outcomes in taxane- or anthracycline-based chemotherapy regimens.

Pubmed Link

Your comments

0 Comments